The recent classification criteria sets for primary Sjögren's syn-
MHz transducer a statistically significantly higher median DT was showed in all skin areas, included thighs (p<0.01). Finally, a positive statistically significant correlation was observed between the two transducers in the evaluation of DT (p<0.0001), as well as between both probes and mRSS (p<0.0001 for both). Conclusions: This study suggests that subclinical dermal involvement may be detectable by skin high frequency US already in patients with limited cutaneous SSc. This study confirms that DT can be better assessed in SSc patients by using a 22 MHz US probe, and suggests that DT might be underestimated by using US probes of lower frequency (18 MHz). However, the DT values obtained using both probes resulted significantly correlated together and with the mRSS. Background: Myositis patients may be classified as belonging to one of four clinical groups: dermatomyositis (DM), polymyositis (PM), clinically amyopathic dermatomyositis (CADM) or necrotizing myositis (NM). Alternatively, myositis patients may be classified according to myositis autoantibody status. Objectives: The aim of this study was to determine whether clinical groups or myositis autoantibodies provide better prognostic categories with regard to muscle involvement in these patients. Methods: All Johns Hopkins Myositis Center patients from 2002 to 2015 with a myositis specific autoantibody confirmed by two different immunologic techniques were included. Autoantibody groups accounting for less than 2% of the final sample size were excluded. Strength (analyzed as the average of deltoid and hip flexor strength using Kendall's scale) and log transformed CK levels were compared between the different autoantibody groups using multilevel regression models adjusted for age, time from disease onset, sex, race and treatments. Models with different combinations of key variables were compared using the likelihood ratio test to ascertain if autoantibody groups and clinical subgroups provided the same amount of information regarding muscle weakness and CK levels over time. Results: 483 patients with 4181 visits were included and 10 different autoantibody groups were identified. Muscle weakness and CK levels followed a gradient among both antibody and clinical groups. Anti-SRP patients had the greatest weakness, followed by anti-HMGCR, anti-Mi2 and anti-NXP2, and then anti-Jo1. CK levels were highest in anti-HMGCR patients, followed by anti-SRP, anti-PL7, anti-Jo1 and anti-Mi2. Interestingly, strength and CK levels were dissociated in two groups: anti-NXP2 patients had significant weakness with low CK levels and anti-PL7 patients were relatively strong despite high CK levels. Multilevel regression models showed autoantibody groups explained the strength and the CK variability better than the clinical groups (AIC difference>20). Indeed, adding clinical groups to a model using only autoantibodies did not improve the model's ability to predict strength (p=0.2) and only mildly improved its ability to predict CK (p=0.01). In comparison, adding the autoantibodies to a model using the clinical groups resulted in a marked improvement in predicting both CK and strength (both p<0.001). Background: Systemic lupus erythematosus (SLE) has been associated with an increased mortality rate. However, population-based data on all-cause, agespecific and sex-specific mortality risk are limited and data on the influence of medication exposure on mortality risk in SLE are scarce. Objectives: To estimate the magnitude of the risk from all-cause, age-specific, and sex-specific mortality in patients with SLE and relative risks compared with matched controls, and to evaluate the influence of medication exposure on mortality risk in SLE. Methods: We conducted a population-based cohort study using the Clinical Practice Research Datalink (from 1987 to 2012). Each SLE patient (n=4356) was matched with up to 6 controls (n=21845) by age and sex. Multivariate Cox regression analysis estimated adjusted relative rates (RR) of mortality, and time interaction terms to evaluate mortality timing patterns. Time-dependent Cox models were used to evaluate the association of glucocorticoid use and hydroxychloroquine use on mortality and were adjusted for age, sex, lifestyle parameters, comorbidities and comedication. Results: A total of 442 out of 4356 SLE patients died during the study period. Patients with SLE had an increased mortality rate for all-cause mortality compared with age-and sex-matched subjects, after adjustment for confounders (adjusted RR 1.80, 95% CI 1.57-2.08). Glucocorticoid use in the previous six months raised the mortality rate while the adjusted RR was 45% decreased with low dose hydroxychloroquine use. The RR was highest in patients aged 18-39 years (adjusted RR 4.87, 95% CI 1.93-12.3) and slightly higher in females (adjusted RR 1.82, 95% CI 1.56-2.13) compared to male patients (adjusted RR 1.68, 95% CI 1.19-2.39). The mortality rate was significantly increased for patients with a history of dementia, seizures, diabetes, cancer, and renal disease (Table 1) . Background: SLE is associated with increased risk of overall mortality; however morality trends due to specific causes including cardiovascular disease (CVD), malignancies or other causes are largely unknown. Objectives: Our objective was to assess trends in cause-specific mortality among SLE patients between January 1, 1997 and December 31, 2012 in a general population-based context. Methods: We conducted a population-based matched cohort on SLE patients diagnosed between January 1,1997 and December 31,2012 using an administrative health database from the province of British Columbia, Canada. We identified all incident cases of SLE and up to 10 non-SLE controls matched on sex, age, and calendar year of study entry. The cohort was divided into two cohorts based on year of SLE diagnosis (1997-2004 and 2005-2012) . All-cause mortality and cause-specific incidence of death rates (IR) were calculated. Cox proportional hazard regression models were used to estimate the mortality hazard ratios (HR), adjusting for possible confounders (i.e. Charlson Comorbidity Index, number of outpatient visits, hospitalization, cardiovascular medications, glucocorticoids and NSAIDs at baseline).
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